Fennell DA - Search Results

1

Estrogen receptor-beta affects the prognosis of human malignant mesothelioma.

Pinton G, Brunelli E, Murer B, Puntoni R, Puntoni M, Fennell DA, Gaudino G, Mutti L, Moro L. Pinton G, et al. Among authors: fennell da. Cancer Res. 2009 Jun 1;69(11):4598-604. doi: 10.1158/0008-5472.CAN-08-4523. Cancer Res. 2009. PMID: 19487281

2

In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion.

Szlosarek PW, Klabatsa A, Pallaska A, Sheaff M, Smith P, Crook T, Grimshaw MJ, Steele JP, Rudd RM, Balkwill FR, Fennell DA. Szlosarek PW, et al. Among authors: fennell da. Clin Cancer Res. 2006 Dec 1;12(23):7126-31. doi: 10.1158/1078-0432.CCR-06-1101. Clin Cancer Res. 2006. PMID: 17145837

3

Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma.

Fennell DA, Steele JP, Shamash J, Evans MT, Wells P, Sheaff MT, Rudd RM, Stebbing J. Fennell DA, et al. Cancer. 2007 Jan 1;109(1):93-9. doi: 10.1002/cncr.22366. Cancer. 2007. PMID: 17146783 Free article.

4

BCL-2 family regulation by the 20S proteasome inhibitor bortezomib.

Fennell DA, Chacko A, Mutti L. Fennell DA, et al. Oncogene. 2008 Feb 21;27(9):1189-97. doi: 10.1038/sj.onc.1210744. Epub 2007 Sep 10. Oncogene. 2008. PMID: 17828309 Review.

5

Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.

Sartore-Bianchi A, Gasparri F, Galvani A, Nici L, Darnowski JW, Barbone D, Fennell DA, Gaudino G, Porta C, Mutti L. Sartore-Bianchi A, et al. Among authors: fennell da. Clin Cancer Res. 2007 Oct 1;13(19):5942-51. doi: 10.1158/1078-0432.CCR-07-0536. Clin Cancer Res. 2007. PMID: 17908991 Free article.

6

Advances in the systemic therapy of malignant pleural mesothelioma.

Fennell DA, Gaudino G, O'Byrne KJ, Mutti L, van Meerbeeck J. Fennell DA, et al. Nat Clin Pract Oncol. 2008 Mar;5(3):136-47. doi: 10.1038/ncponc1039. Nat Clin Pract Oncol. 2008. PMID: 18227828 Review.

7

In arrayed ranks: array technology in the study of mesothelioma.

Gray SG, Fennell DA, Mutti L, O'Byrne KJ. Gray SG, et al. Among authors: fennell da. J Thorac Oncol. 2009 Mar;4(3):411-25. doi: 10.1097/JTO.0b013e3181951ce8. J Thorac Oncol. 2009. PMID: 19247089 Free article. Review.

8

Malignant pleural mesothelioma: current treatments and emerging drugs.

Belli C, Fennell D, Giovannini M, Gaudino G, Mutti L. Belli C, et al. Expert Opin Emerg Drugs. 2009 Sep;14(3):423-37. doi: 10.1517/14728210903074563. Expert Opin Emerg Drugs. 2009. PMID: 19552609 Review.

9

Translational therapies for malignant pleural mesothelioma.

Belli C, Anand S, Tassi G, Fennell D, Mutti L. Belli C, et al. Expert Rev Respir Med. 2010 Apr;4(2):249-60. doi: 10.1586/ers.10.17. Expert Rev Respir Med. 2010. PMID: 20406091 Review.

10

Will antiangiogenic agents be a future for mesothelioma therapy?

Belli C, Anand S, Panella M, Giovannini M, Tassi G, Fennell D, Mutti L. Belli C, et al. Curr Med Chem. 2010;17(27):3069-79. doi: 10.2174/092986710791959710. Curr Med Chem. 2010. PMID: 20629625 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

212 results

Search Page

Filters